Your browser doesn't support javascript.
loading
Implementation of a light therapy team to administer photobiomodulation therapy: A standardized protocol to prevent and treat oral mucositis in the pediatric hematopoietic stem cell transplant population.
Magee, Kathleen; Robins, Jenell; Staton, Sharon; Llaurador, Gabriella; Stevens, Alexandra M.
Afiliación
  • Magee K; Texas Children's Cancer and Hematology Centers, Houston, Texas, USA.
  • Robins J; Texas Children's Cancer and Hematology Centers, Houston, Texas, USA.
  • Staton S; Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
  • Llaurador G; Texas Children's Cancer and Hematology Centers, Houston, Texas, USA.
  • Stevens AM; Texas Children's Cancer and Hematology Centers, Houston, Texas, USA.
Pediatr Blood Cancer ; 71(6): e30966, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38556719
ABSTRACT

BACKGROUND:

Oral mucositis (OM) is a painful and common complication of hematopoietic stem cell transplant (HSCT). The Children's Oncology Group recently published guidelines recommending photobiomodulation (PBM) for preventing and treating OM in pediatric HSCT patients. However, this is a rarely used intervention in pediatric hospitals. PROCEDURE Patients undergoing allogeneic HSCT, or autologous HSCT for a neuroblastoma diagnosis, had PBM administered from the first day of conditioning to transplant Day +20. We successfully developed a standardized treatment protocol and workflow to ensure consistent and uniform delivery of PBM. In addition, clinical patient data were compared before and after PBM implementation.

RESULTS:

The administration of PBM at our center was feasible, but required dedicated staff. A registered nurse (RN) was determined to be the best fit to deliver PBM. Sixty-two patients received PBM from October 2022 to September 2023; patients from 2021 before PBM implementation were used for comparison. Patients receiving PBM were more likely (p = .03) to engage in teeth brushing (56/62 = 90%) compared to baseline (61/81 = 75%). Mean days of OM decreased from 11.3 to 9 days; patients who received PBM were less likely (p < .001) to be discharged on total parental nutrition (TPN) (11/62 = 18%) compared to baseline (50/82 = 61%). OM-related supportive care costs (TPN and patient-controlled anesthesia [PCA]) were lower (p = .02) for those who received PBM (median cost = $31,229.87 vs. $37,370.66).

CONCLUSION:

PBM, as the standard of care in the pediatric HSCT population, is safe, feasible, and well-tolerated. At our center, a dedicated RN was critical to providing standardized treatment and ensuring sustainability.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Estomatitis / Trasplante de Células Madre Hematopoyéticas / Terapia por Luz de Baja Intensidad Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Estomatitis / Trasplante de Células Madre Hematopoyéticas / Terapia por Luz de Baja Intensidad Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos